A Multi-Center Phase III Study of Autologous Transplantation for Patients with Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine with Melphalan 200 mg/m2 + Amifostine

Trial Profile

A Multi-Center Phase III Study of Autologous Transplantation for Patients with Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine with Melphalan 200 mg/m2 + Amifostine

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2015

At a glance

  • Drugs Melphalan (Primary) ; Amifostine
  • Indications Multiple myeloma; Various toxicities
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Sep 2015 Results published in the Bone Marrow Transplantation.
    • 20 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Dec 2012 Primary endpoint `Major clinical response rate (near complete response and better)' has been met, according to the abstract presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top